Novo Nordisk A/S (NYSE:NVO) Posts Quarterly Earnings Results, Beats Expectations By $0.11 EPS

Novo Nordisk A/S (NYSE:NVO) issued its quarterly earnings data on Tuesday. The company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.90 by $0.11, FiscalAI reports. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%.

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO traded down $7.32 during trading on Tuesday, reaching $51.61. 39,805,348 shares of the company traded hands, compared to its average volume of 22,574,135. The firm has a 50 day simple moving average of $53.72 and a 200-day simple moving average of $54.28. The stock has a market capitalization of $230.44 billion, a PE ratio of 14.91 and a beta of 0.66. The company has a quick ratio of 0.57, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a 52-week low of $43.08 and a 52-week high of $93.80.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. State Street Corp boosted its holdings in shares of Novo Nordisk A/S by 1.0% during the 3rd quarter. State Street Corp now owns 6,106,836 shares of the company’s stock valued at $340,125,000 after purchasing an additional 59,153 shares during the last quarter. Boston Partners bought a new stake in shares of Novo Nordisk A/S during the third quarter worth $310,199,000. Northern Trust Corp raised its stake in shares of Novo Nordisk A/S by 4.3% during the third quarter. Northern Trust Corp now owns 4,611,126 shares of the company’s stock valued at $255,871,000 after acquiring an additional 189,640 shares in the last quarter. Saratoga Research & Investment Management raised its holdings in shares of Novo Nordisk A/S by 22.5% in the third quarter. Saratoga Research & Investment Management now owns 1,853,707 shares of the company’s stock valued at $102,862,000 after acquiring an additional 341,030 shares in the last quarter. Finally, Ameriprise Financial Inc. raised its stake in Novo Nordisk A/S by 11.6% in the second quarter. Ameriprise Financial Inc. now owns 1,609,480 shares of the company’s stock worth $109,973,000 after buying an additional 167,185 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: CagriSema showed superior HbA1c and weight-loss results versus semaglutide in a late‑stage trial, strengthening Novo’s next‑generation diabetes/obesity pipeline and long‑term revenue prospects. Novo Nordisk says CagriSema outperforms semaglutide
• Positive Sentiment: Full‑year 2025 sales beat analyst expectations (sales up ~10%) and operating profit rose, indicating strong recent execution even as growth guidance slows. Novo Nordisk Posts Better-Than-Expected 2025 Sales
• Positive Sentiment: Leadership change in the U.S.: Jamey Millar named head of U.S. business (and Hong Chow head of product/portfolio strategy), a governance move aimed at commercial focus during a challenging market. Wegovy maker Novo Nordisk appoints Jamey Millar head of its US business
• Positive Sentiment: Some brokers remain bullish (e.g., Kepler kept a buy rating), signaling continued analyst confidence in the franchise despite the pullback. Kepler Capital Sticks to Its Buy Rating for Novo Nordisk
• Neutral Sentiment: Trading in NVO was temporarily halted for a “news pending” announcement, contributing to intraday volatility but not clarifying fundamentals by itself.
• Neutral Sentiment: Analysts (Citi) note the CagriSema headline data were expected and that more consequential comparisons (e.g., head‑to‑head with Eli Lilly’s tirzepatide) remain ahead—so near‑term investor focus shifts to upcoming readouts. Citi flags bigger tests ahead after Novo Nordisk diabetes trial success
• Negative Sentiment: Management guided to a 2026 sales decline (‑5% to ‑13% at constant FX) and lower profit growth, citing U.S. market weakness—this is the primary near‑term catalyst for the stock’s drop. Wegovy Maker Novo Nordisk Forecasts Sales Decline in 2026
• Negative Sentiment: Shares fell sharply after the outlook was released, reflecting investor concern about near‑term revenue and U.S. pricing/execution risks. Novo Nordisk shares tumble 11% after company forecasts sales declines this year
• Negative Sentiment: Industry note: analysts warn the obesity/GLP‑1 market’s revenue potential is being re‑priced as U.S. prices fall and competition heats up, tightening the long‑term sales outlook for major players. Obesity market sales potential tightens as Novo and Lilly enter new era

Wall Street Analyst Weigh In

A number of brokerages recently commented on NVO. Jefferies Financial Group began coverage on Novo Nordisk A/S in a research report on Monday, October 27th. They set an “underperform” rating for the company. Weiss Ratings reiterated a “sell (d+)” rating on shares of Novo Nordisk A/S in a research report on Monday, December 29th. HSBC restated a “hold” rating and set a $54.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, December 10th. Citigroup assumed coverage on Novo Nordisk A/S in a report on Tuesday, January 27th. They set a “neutral” rating for the company. Finally, Argus restated a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $57.79.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.